Reuters logo
BRIEF-Gemphire announces plans to advance gemcabene into phase 3 clinical development
September 19, 2017 / 8:22 PM / 3 months ago

BRIEF-Gemphire announces plans to advance gemcabene into phase 3 clinical development

Sept 19 (Reuters) - Gemphire Therapeutics Inc

* Gemphire announces plans to advance gemcabene into phase 3 clinical development

* Gemphire Therapeutics Inc - ‍End of phase 2 meetings planned for early 2018​

* Says gemcabene successfully achieved primary endpoint in two recently completed phase 2B studies

* Gemphire Therapeutics - Results from all 20 clinical studies in 956 patients were exposed to gemcabene have demonstrated gemcabene is well tolerated and safe​

* Gemphire-New analysis shows 600 mg of gemcabene reduced ldl-c by 21% in hypercholesterolemic patients, by 25% in mixed dyslipidemic patients in trials

* Gemphire - Also plans to develop gemcabene as monotherapy or as add-on therapy to diet and other lipid lowering therapies for treatment of SHTG Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below